Article contents
‘From Felix to the helix, and from the cradle to the grave – Semon's contribution to thyroid surgery’, Royal Society of Medicine, 1 November 2019, London, UK
Published online by Cambridge University Press: 29 May 2020
Extract
Mr President, Mr President Elect, Fellows and Members, Ladies and Gentleman, it is a pleasure to address the Section of Laryngology this morning and deliver the 94th Semon Lecture. I would like to thank the Semon Committee for their kind invitation. My lecture will discuss Sir Felix Semon (the man himself), highlight the history of head and neck surgery, and then discuss the requirements of a modern-day thyroid surgeon. I have no conflict of interest and nothing to declare.
- Type
- Lecture
- Information
- Copyright
- Copyright © The Author(s), 2020. Published by Cambridge University Press
References
Semon, HC, McIntyre, TA. The Autobiography of Sir Felix Semon KCVO MD FRCP. London: Jarrolds, 1926Google Scholar
Harrison, D. Felix Semon (1849–1921): a Victorian Laryngologist. London: Royal Society of Medicine Press, 2000Google Scholar
Weir, N, Mudry, A. Otorhinolaryngology: An Illustrated History, 2nd edn. Ashford: Headleys, 2013Google Scholar
Watkinson, JC, Gilbert, RW, eds. Stell & Maran's Textbook of Head and Neck Surgery and Oncology, 5th edn. London: Hodder Arnold, 2012Google Scholar
Watkinson, JC, Clarke, RW, eds. Scott-Brown's Otorhinolaryngology, Head and Neck Surgery, Volume 1, 8th edn. Boca Raton, FL: CRC Press (Taylor Francis Group), 2019Google Scholar
Watkinson, JC, Street, I, Harrison, S. Avoiding complications in thyroid surgery, including how we do it: the thirty-nine steps. ENT News 2007;15:80–3Google Scholar
Watkinson, JC. Fifteen years’ experience in thyroid surgery. Ann R Coll Surg Engl 2010;92:541–7CrossRefGoogle ScholarPubMed
Gittoes, NJK, Miller, MR, Kaykin, J, Sheppard, MC, Franklyn, JA. Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement. BMJ 1996;312:484CrossRefGoogle ScholarPubMed
Wagner, R. The median position of the vocal cords in recurrent paralysis [in German]. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medizin 1890;120:437–59Google Scholar
Grossman, M. Experimental contributions to the teaching of 'post paralysis'. Archa Laryngologie und Rhinologie 1897;6:282–360Google Scholar
Henry, BM, Pękala, PA, Sanna, B, Vikse, J, Sanna, S, Saganiak, K et al. The anastomoses of the recurrent laryngeal in the larynx nerve in the larynx: a meta-analysis and systematic review. J Voice 2017;31:495–503CrossRefGoogle ScholarPubMed
British Thyroid Association. Guidelines for the Management of Thyroid Cancer, 3rd edn. Report of the Thyroid Cancer Guidelines Update Group. London: RCP, 2014Google Scholar
Nixon, IJ, Shaha, AR. Management of locoregionally recurrent differentiated thyroid cancer. In: Watkinson, JC, Clarke, RW, eds. Scott-Brown's Otolaryngology, Head & Neck Surgery, Volume 1, 8th edn. Boca Raton, FL: CRC Press (Taylor Francis Group), 2018;773–8CrossRefGoogle Scholar
Ishii, H, Kim, DS, Watkinson, JC. Management of cervical lymph nodes in differentiated thyroid cancer. In: Mallick, UJ, Harmer, C, Mazzaferri, EL, Kendall-Taylor, P, eds. Practical Management of Thyroid Cancer: A Multidisciplinary Approach, 2nd edn. Cham: Springer, 2018Google Scholar
Warner, L, Jennings, C, Watkinson, JC. Surgical anatomy of the neck. In: Watkinson, JC, Clarke, RW, eds. Scott-Brown's Otolaryngology, Head & Neck Surgery, Volume 3, 8th edn. Boca Raton, FL: CRC Press (Taylor Francis Group), 2018;541–64Google Scholar
Montgomery (Appellant) v Lanarkshire Health Board (Respondent) & General Medical Council (Intervener) [2015]. UKSC 11. Case Library, 12 King's Bench Walk, 2015Google Scholar
Susarla, R, Watkinson, JC, Eggo, MC. Regulation of human thyroid follicular cell function by inhibition of vascular endothelial growth factor receptor signalling. Mol Cell Endocrinol 2012;351:199–207CrossRefGoogle ScholarPubMed
Kim, DS, Franklyn, JA, Boelaert, K, Eggo, MC, Watkinson, JC, McCabe, CJ. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway. J Clin Endocrinol Metab 2006;91:4603–11CrossRefGoogle Scholar
Ramsden, JD, Buchanan, MA, Egginton, S, Watkinson, JC, Mautner, V, Eggo, MC. Complete inhibition of goiter in mice requires combined gene therapy modification of angiopoietin, vascular endothelial growth factor, and fibroblast growth factor signaling. Endocrinology 2005;146:2895–902CrossRefGoogle ScholarPubMed
Smith, VE, Read, ML, Turnell, AS, Watkins, RJ, Watkinson, JC, Lewy, GD et al. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci 2009;122(Pt 18):3393–402CrossRefGoogle ScholarPubMed
Wang, JR, Zafereo, ME, Dadu, R, Ferrarotto, R, Busaidy, NL, Lu, C et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E- mutated anaplastic thyroid carcinoma. Thyroid 2019;29:1036–43CrossRefGoogle ScholarPubMed
Smith, J, Read, ML, Hoffman, J, Brown, R, Bradshaw, B, Campbell, C et al. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression. Hum Mol Genet 2016;25:1836–45CrossRefGoogle ScholarPubMed
Read, ML, Seed, RI, Fong, JC, Modasia, B, Ryan, GA, Watkins, RJ et al. The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. Endocrinology 2014;155:1222–34CrossRefGoogle ScholarPubMed
Read, M, Fong, J, Imruetaicharoenchoke, W, Modasia, B, Nieto, H, Watkinson, J et al. Comparative analysis of human and mouse expression data identifies distinct proto-oncogene PTTG- and PBF-associated genes in thyroid cancer. Eur J Cancer 2016;61(suppl 1):S36CrossRefGoogle Scholar
Almubarak, H, Qassem, E, Alghofaili, L, Alzahrani, AS, Karakas, B. Non-invasive molecular detection of minimal residual disease in papillary thyroid cancer patients. Front Oncol 2020;9:1510CrossRefGoogle ScholarPubMed
Allin, DM, Shaikh, R, Carter, P, Thway, K, Sharabiai, MTA, Gonzales-de-Castro, D et al. Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. Eur J Cancer 2018;103:165–7510.1016/j.ejca.2018.08.013CrossRefGoogle ScholarPubMed
- 1
- Cited by